ALLMedicine™ Gastrointestinal Tumors Center
Research & Reviews 321 results
https://doi.org/10.1097/MD.0000000000029364
Medicine Wang G, Pan L et. al.
Jun 28th, 2022 - During the coronavirus disease 2019 (COVID-19) pandemic, endoscopic screening for gastrointestinal tumors was suspended or delayed in most countries. Thus, our study aimed to quantify the impact of COVID-19 on the clinical outcomes of patients wit...
https://clinicaltrials.gov/ct2/show/NCT05430841
Jun 24th, 2022 - Subjects with gastrointestinal tumors underwent contemporaneous 18F-AlF-FAPI and 18F-FDG PET/CT either for an initial assessment or for recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The numbers of...
https://clinicaltrials.gov/ct2/show/NCT00044304
Jun 24th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...
https://clinicaltrials.gov/ct2/show/NCT05427227
Jun 22nd, 2022 - The investigators will recruit 500 advancer/late-stage gastrointestinal cancer patients.Blood and tumor tissue will be collected at treatment baseline, every time point response till disease progression. All samples will be processed by exosomes p...
https://clinicaltrials.gov/ct2/show/NCT05182983
Jun 16th, 2022 - The tongue images of patients with gastrointestinal diseases and healthy people will be collected and the tongue image database will be established. Through deep learning and artificial intelligence, early screening models of various gastrointesti...
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977951
World Journal of Gastroenterology; Marc G, Lopes CV
Aug 14th, 2008 - Therapeutic endoscopy plays a major role in the management of gastrointestinal (GI) neoplasia. Its indications can be generalized into four broad categories; to remove or obliterate neoplastic lesion, to palliate malignant obstruction, or to treat...
Drugs 5 results see all →
Clinicaltrials.gov 61 results
https://clinicaltrials.gov/ct2/show/NCT05430841
Jun 24th, 2022 - Subjects with gastrointestinal tumors underwent contemporaneous 18F-AlF-FAPI and 18F-FDG PET/CT either for an initial assessment or for recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The numbers of...
https://clinicaltrials.gov/ct2/show/NCT00044304
Jun 24th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...
https://clinicaltrials.gov/ct2/show/NCT05427227
Jun 22nd, 2022 - The investigators will recruit 500 advancer/late-stage gastrointestinal cancer patients.Blood and tumor tissue will be collected at treatment baseline, every time point response till disease progression. All samples will be processed by exosomes p...
https://clinicaltrials.gov/ct2/show/NCT05182983
Jun 16th, 2022 - The tongue images of patients with gastrointestinal diseases and healthy people will be collected and the tongue image database will be established. Through deep learning and artificial intelligence, early screening models of various gastrointesti...
https://clinicaltrials.gov/ct2/show/NCT05411133
Jun 9th, 2022 - This study aims to find out: The tolerability of ARB202 in adults with advanced solid gastrointestinal tumors who failed the standard treatment. People can participate if their tumor has the CDH17 marker. To find out how study drug is broken down ...
News 23 results
https://www.onclive.com/view/average-cumulative-relative-adjuvant-chemo-dose-linked-with-survival-in-crc
Aug 17th, 2021 - Average cumulative relative dose (ACRD) was found to be associated with survival over average relative dose intensity (ARDI) in patients with colorectal cancer (CRC), highlighting that obese patients receive lower cumulative doses of adjuvant chem...
https://www.onclive.com/view/optimal-approach-toward-advanced-gastric-cancers-in-us
Apr 2nd, 2021 - Johanna Bendell, MD: In Japan, there are screening protocols that catch these cancers early so they can be cured before they get to an advanced setting. Here in the United States, we don’t have that so much. How are we trying to work to look at ea...
https://www.onclive.com/view/the-evolving-story-of-mutational-landscape-in-cancer-and-its-implications-bad-luck-or-great-hope
Dec 20th, 2020 - Andre Goy, MD Editor-in-Chief of Oncology & Biotech News Chairman and Director Chief of Lymphoma Director, Clinical and Translational Cancer Research John Theurer Cancer Center at Hackensack University Medical Center While it is...
https://www.onclive.com/view/survival-benefit-observed-with-cetuximab--in-ras-wild-type-colorectal-cancer
Dec 20th, 2020 - Volker Heinemann, MD, PhD Cetuximab (Erbitux) plus FOLFIRI may offer a survival advantage over FOLFIRI plus bevacizumab (Avastin) in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer who do not have RAS mu...
https://www.onclive.com/view/regorafenib-extends-pfs-in-locally-advanced-biliary-tract-cancer
Dec 20th, 2020 - The oral multi-kinase inhibitor regorafenib extended progression-free survival (PFS) in patients with metastatic or unresectable biliary tract cancer (BTC) who were previously treated with gemcitabine (Gemzar) and a platinum-based chemotherapy, ac...
